Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Synthetic Biologics, Inc. SYN
$1.02
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
16160982.00000000
-
week52high
4.55
-
week52low
0.70
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.38872500
-
EPS
-0.12000000
-
Last Dividend
0.00000000
-
Next Earnings Date
14 мар 2023 г. в 04:00
Описание компании
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Griffin Securities | Hold | Buy | 10 мая 2018 г. |
| FBR Capital | Outperform | Outperform | 26 февр 2016 г. |
| RBC Capital | Outperform | Outperform | 13 окт 2015 г. |
| BTIG Research | Buy | Buy | 25 авг 2015 г. |
| William Blair | Outperform | Outperform | 01 июн 2015 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Wolf Jeffrey Alan | A | 200000 | 200000 | 23 дек 2021 г. |
| SHALLCROSS STEVEN A | A | 650000 | 650000 | 23 дек 2021 г. |
| MONAHAN JOHN J | A | 200000 | 200000 | 23 дек 2021 г. |
| Kraws Jeffrey J | A | 200000 | 200000 | 23 дек 2021 г. |
| SHALLCROSS STEVEN A | A | 100000 | 50000 | 10 мая 2021 г. |
| SHALLCROSS STEVEN A | A | 450000 | 450000 | 30 дек 2020 г. |
| Wolf Jeffrey Alan | A | 150000 | 150000 | 30 дек 2020 г. |
| Kraws Jeffrey J | A | 150000 | 150000 | 30 дек 2020 г. |
| MONAHAN JOHN J | A | 150000 | 150000 | 30 дек 2020 г. |
| SHALLCROSS STEVEN A | A | 450000 | 450000 | 04 дек 2019 г. |
Новостная лента
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
11 авг 2022 г. в 12:19
Synthetic Biologics, Inc. (NYSE:SYN ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive & Chief Financial Officer Manel Cascallo - General Director of VCN & European Operations Conference Call Participants Laura Suriel - Alliance Global Partners Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Synthetic Biologics' Second Quarter 2022 Earnings Call. Today's conference is being recorded.
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q1 2022 Results - Earnings Call Transcript
Seeking Alpha
16 мая 2022 г. в 17:06
Synthetic Biologics, Inc. (NYSE:SYN ) Q1 2022 Earnings Conference Call May 16, 2022 9:00 AM ET Company Participants Dean Schwartz - LifeSci Advisors, IR Steven Shallcross - CEO and CFO Manel Cascallo - General Director of VCN & European Operations Conference Call Participants Jim Molloy - Alliance Global Partners Leland Gershell - Oppenheimer Operator Greetings, and welcome to Synthetic Biologics' First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.
Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results
GlobeNewsWire
09 мая 2022 г. в 08:00
ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update.